Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment.

Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price, making it more affordable for clinically eligible individuals.

The collaboration integrates diagnosis, prescription, and home delivery into one platform.

Also Read: Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility

Eli Lilly's executive vice president, Patrik Jonsson, emphasized the importance of affordability and accessibility in obesity care, noting that Zepbound's lower-cost vials represent a significant step toward breaking down barriers. "Our goal is to provide safe and effective treatment options that patients can trust," Jonsson stated.

"Lilly's release of Zepbound single-dose vials at a lower, self-pay-only price was groundbreaking and reflects the patient-centric model upon which Ro was founded. This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without patients ever having to leave the Ro app, let alone leave their home," said Zach Reitano, co-founder & CEO of Ro.

CNBC notes that the collaboration enables eligible patients to access Zepbound through a "complete end-to-end" experience. Patients can receive a diagnosis, obtain a prescription, and have the medication delivered directly to their homes via Gifthealth, a digital pharmacy partnered with LillyDirect.

Zepbound vials are cash-pay products priced at $399 for a 2.5 mg dose and $549 for a 5 mg dose.

Ro also provides extensive ongoing support for weight management, including personalized care plans, 24/7 access to licensed physicians, coaching, and tools for monitoring progress.

Using data, the platform helps patients choose the most cost-effective medication, whether through insurance or cash payment.

Ro additionally assists with prescriptions for Novo Nordisk A/S' (NYSE:NVO) rival drug, Wegovy (semaglutide), and compounded alternatives.

Last week, Eli Lilly revealed topline data from the SURMOUNT-5 phase 3b trial of Zepbound (tirzepatide) compared with Novo Nordisk's Wegovy (semaglutide) in adults with obesity, or overweight with at least one of the following comorbidities.

Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.

Price Action: At last check Thursday, LLY stock was up 0.31% at $798.50.

Read Next:

• Kroger's $7.5 Billion Buyback Blitz: Eyes Lower Grocery Prices And Big Returns After Albertsons Pivot

Photo Source: Eli Lilly and Company